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Background/Aims: Acoustic radiation force impulse (ARFI) 
elastography predicts the presence of esophageal varices 
(EVs). We investigated whether an ARFI-based prediction 
model can assess EV bleeding (EVB) risk in patients with cir-
rhosis. Methods: The records of 262 patients with cirrhosis 
who underwent ARFI elastography and endoscopic surveil-
lance at two institutions in 2008 to 2013 were retrospec-
tively reviewed, and ARFI–spleen diameter-to-platelet ratio 
scores (ASPS) were calculated. Results: The median patient 
age (165 men, 97 women) was 56 years. The median ARFI 
velocity, spleen diameter, platelet count, and ASPS were 1.7 
m/sec, 10.1 cm, 145×109/L, and 1.16, respectively. During 
the median 38-month follow-up, 61 patients experienced 
EVB. Among all patients (179 without EVs and 83 with EVs), 
the cutoff value that maximized the sum of the sensitivity 
(73.1%) and specificity (78.4%) (area under receiver operat-
ing characteristic curve [AUROC], 0.824) for predicting EVB 
was 2.60. The cumulative EVB incidence was significantly 
higher in patients with ASPS ≥2.60 than in those with ASPS 
<2.60 (p<0.001). Among patients with EVs (n=83), 49 had 
high-risk EVs (HEVs), and 22 had EVB. The cumulative EVB 
incidence was significantly higher in HEV patients than in 
low-risk EV patients (p=0.037). At an ASPS of 4.50 (sensitiv-
ity, 66.7%; specificity, 70.6%; AUROC, 0.691), the cumula-
tive EVB incidence was significantly higher in patients with 
a high ASPS than in those with a low ASPS (p=0.045). A 
higher ASPS independently predicted EVB (hazard ratio, 
4.072; p=0.047). Conclusions: ASPS can assess EVB risk 
in patients with cirrhosis. Prophylactic management should 
be considered for patients with HEVs and ASPS ≥4.50. (Gut 
Liver 2019;13:206-214)
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INTRODUCTION
 Esophageal varices (EVs) are an important complication af-
fecting approximately 50% of patients with cirrhosis depending 
on the clinical stage.1 EVs are present in 30% to 40% of patients 
with compensated cirrhosis and in up to 85% of patients with 
decompensated cirrhosis.2 In patients with compensated cirrho-
sis, new varices develop at a rate of 7% to 8% per year.3 Small 
varices can progress to large varices at a rate of 10% to 12% per 
year; therefore, patients with small varices are at a higher risk of 
bleeding.4
Esophageal variceal bleeding (EVB) occurs at a rate of 10% to 
15% yearly,5 and acute EVB reportedly has a 6-week mortality 
rate of 15% to 25%.6-8 Since EVB is a life-threatening compli-
cation of patients with cirrhosis, the current guidelines recom-
mend both screening endoscopy for high-risk patients with 
cirrhosis to identify whether primary prophylactic treatment 
should be considered and repeated endoscopic surveillance.1,9,10 
To determine EVB risk, the presence and size of varices and 
presence of the color red requires endoscopy, an invasive and 
expensive procedure that is not risk-free.5,11 Thus, based on the 
current European (Baveno VI) and American (American Associ-
ation for the Study of Liver Diseases) recommendations, patients 
with liver stiffness (LS) <20 kPa and platelet count >150,000/
mm3 were suggested to avoid endoscopy by undergoing annual 
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surveillance of platelet count and EVs via transient elastogra-
phy (TE).1,9 Similarly, Kim et al.,12 showed a measurement-based, 
noninvasive prediction model of LS, the LS–spleen diameter to 
platelet ratio score (LSPS), that reliably detected high-risk EVs 
(HEVs). 
Recently, acoustic radiation force impulse (ARFI) imaging has 
been suggested as an alternative method for noninvasive assess-
ments of liver fibrosis and portal hypertension.13,14 Some studies 
have shown that ARFI elastography is a reliable technique for 
predicting portal hypertension.15,16 Morishita et al.16 reported 
that the ARFI value can predict the presence of EVs and HEVs 
among patients with HCV-related cirrhosis, with area under the 
receiver operating characteristic curve (AUROC) values of 0.890 
and 0.868, respectively. Most recently, Park et al.17 suggested 
a noninvasive ARFI-based prediction model called the ARFI–
spleen diameter-to-platelet ratio score (ASPS), which accurately 
identifies HEVs in patients with compensated cirrhosis. In this 
study, the ASPS predicted HEVs with an AUROC value of 0.946, 
and an ASPS value of 5.28 was suggested as the cutoff for 
considering endoscopic examinations or appropriate prophylac-
tic treatment. However, no study has investigated whether an 
ARFI-based prediction model can assess the forthcoming risk of 
EVB in patients with cirrhosis. 
Here, we investigated the predictive role of the ASPS in as-
sessing the risk of EVB in patients at two tertiary academic in-
stitutions in Korea.
MATERIALS AND METHODS
1. Patients
Between 2010 and 2013, we retrospectively recruited 291 pa-
tients with compensated cirrhosis who underwent ARFI elastog-
raphy and endoscopic surveillance at Severance Hospital, Yon-
sei University College of Medicine, Seoul, Korea (n=143) and at 
Kyungpook National University Hospital, School of Medicine, 
Kyungpook National University, Daegu, Korea (n=148). This 
study cohort included patients described in our previous study.17 
Compensated cirrhosis was defined as evident cirrhosis in the 
absence of any previous or current known complications of 
portal hypertension, including ascites, variceal bleeding, and/or 
hepatic encephalopathy.18,19 Cirrhosis was diagnosed using stan-
dard laboratory, radiological, and physical examination findings 
or by liver histology in equivocal cases.
Exclusion criteria were as follows: (1) >6 months between 
ARFI elastography and endoscopic surveillance, (2) Child-Pugh 
C class, (3) hepatic decompensation including current or past 
history of EVs, (4) current or past history of hepatocellular car-
cinoma, (5) previous or current history of treatment for portal 
hypertension, (6) history of splenectomy, (7) ARFI measurement 
failure or unreliable measurement, (8) presence of portal vein 
thrombosis, and (9) right-sided heart failure. 
The study protocol was performed according to the ethical 
guidelines of the 1975 Declaration of Helsinki. Written informed 
consent was not required due to the retrospective nature of this 
multicenter study. This study was approved by the Institutional 
Review Board of Severance Hospital, Yonsei University College 
of Medicine (IRB No. 2012-0015-001) and Kyungpook Univer-
sity Hospital (IRB No. 2015-09-030). 
2. Clinical and laboratory variables 
Demographic data, including age, sex, body mass index, and 
other clinical and laboratory parameters were recorded for each 
patient at the time the ARFI measurements were taken. Clinical 
parameters included a previous history of treatment for EVs or 
portal hypertension, and laboratory parameters included hemo-
globin, alanine aminotransferase, aspartate aminotransferase, 
serum albumin, total bilirubin, prothrombin time, and platelet 
count. The Child-Pugh class was assessed based on these pa-
rameters.
3. Imaging techniques
Standard ultrasonographic scanning of the abdomen, in-
cluding measurement of the maximum spleen diameter and 
ARFI elastography, were performed under fasting conditions. 
The spleen diameter was defined as the bipolar diameter at the 
crossing point of the spleen hilum20 and was measured using 
electronic calipers. ARFI elastography was performed on each 
patient using a Siemens Acuson S2000 ultrasound system (Sie-
mens Healthcare GmbH, Erlangen, Germany) by expert sonog-
raphers at each institute (all had performed >500 examinations) 
who were blinded to the endoscopy results. LS was measured 
with ARFI elastography, similar to the protocol of our previous 
study.17 ARFI shear wave velocity was measured in meters per 
second (m/sec). The median value of 10 valid measurements 
was calculated. ARFI failure was defined as zero valid shots, and 
unreliable measurements were reported as an interquartile range 
(IQR) to a median value ratio >30% or success rate <60%.15 
4. Endoscopic evaluation and grading of EVs
Endoscopic evaluation and grading of EVs was performed 
by expert endoscopists at each institute (>1,000 examinations) 
who were blinded to the ARFI elastography results. EVs were 
classified as small (veins minimally elevated above the esopha-
geal mucosal surface), medium (tortuous veins occupying less 
than one-third of the esophageal lumen), or large (veins oc-
cupying more than one-third of the esophageal lumen). HEVs 
were defined as medium to large EVs and small EVs with red 
signs, while low-risk EVs were defined as small EVs without red 
signs.21,22
5. Calculation of the ASPS 
The ASPS was calculated as follows: (ARFI velocity [m/
sec]×spleen diameter [cm]/platelet count [109/L]).
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6. Patient follow-up
All patients underwent periodic surveillance with annual en-
doscopy, ultrasonography, and laboratory assessments for EV 
screening and follow-up. Patients with HEVs took the nonselec-
tive β-blocker propranolol as a prophylaxis for EVB after the 
diagnosis of HEV was made if not contraindicated. The dose of 
propranolol was titrated according to the resting pulse rates or 
side effects. Any patient suspected of having upper gastrointes-
tinal bleeding underwent an emergency endoscopy within 12 
hours of presentation to ensure accurate diagnosis and appro-
priate treatment. EVB was defined when hematemesis, hema-
tochezia, or melena was confirmed by endoscopy to originate 
from EVs.
7. Statistical analysis
The primary aim of this longitudinal study was to assess the 
predictive value of the ASPS for assessing the risk of future EVB. 
Continuous variables were compared using the Student t-test or 
the Mann-Whitney U-test, whereas categorical variables were 
compared using the chi-square test or Fisher exact test. To assess 
the predictive value of the model for cumulative bleeding events 
during follow-up, time-dependent ROC curves for the time to 
the first EVB event were constructed, and the AUROC was also 
computed.23 The cutoff values, sensitivity, specificity, negative 
predictive value (NPV), positive predictive value (PPV), positive 
likelihood ratio, and negative likelihood ratio were also calcu-
lated.
The Kaplan-Meier method was used to examine the time to 
the first occurrence of EVB, the primary end point. The log-rank 
test was used to assess variations in EVB episodes. The Cox pro-
portional hazards model was used for the multivariate analyses. 
Variables with p-values <0.10 in the univariate analysis were 
included in the multivariate analysis, and p-values <0.05 were 
considered statistically significant. The data were analyzed us-
ing SPSS 20.0 for Windows (IBM Corp., Armonk, NY, USA) and 
MedCalc Software version 12.7.2 (MedCalc Software bvba, Os-
tend, Belgium). 
RESULTS
1. Baseline characteristics
Of 291 patients screened by the inclusion criteria, 29 were 
excluded, leaving a total of 262 patients who were ultimately 
enrolled (Supplementary Fig. 1). The median interval between 
ARFI elastography and endoscopy was 112 days (IQR, 14 to 154 
days). 
Baseline patient characteristics are summarized in Table 1. 
The mean age was 56.0 years, and 165 patients (63.0%) were 
men. Hepatitis B virus was the most common etiology of cirrho-
sis (n=166, 63.3%). A total of 244 patients (93.1%) were clas-
sified as Child-Pugh class A, whereas 18 (6.9%) were classified 
as Child-Pugh class B. A total of 83 patients (31.7%) had EVs 
(38 small, 27 medium, and 18 large), and 49 (18.7%) had HEVs. 
Portal hypertensive gastropathy was observed in 24 patients 
(9.9%). The median ARFI velocity, platelet count, spleen diam-
eter, and ASPS were 1.7 m/sec, 145×109/L, 10.1 cm, and 1.16, 
respectively.
2. Comparison of patients with and without EVs or HEVs
When patients with and without EVs were compared (Table 2), 
those with EVs were significantly older (median: 57 years vs 56 
years) and were more likely to be male (72.3% vs 58.7%) than 
those without EVs (all p<0.05). In addition, the proportion of 
patients with hypertensive gastropathy was significantly higher 
in the EV group than in the non-EV group (73.5% vs 3.4%, re-
spectively; p<0.001). Patients with EVs had a significantly lower 
hemoglobin level (median: 12.7 g/dL vs 13.7 g/dL), a lower se-
rum albumin level (3.9 g/dL vs 4.2 g/dL), a higher international 
Table 1. Baseline Characteristics of the Entire Population (n=262)
Variable Value
Demographic data
   Age, yr 56.0 (48.0–64.0)
   Male sex 165 (63.0)
   Body mass index, kg/m2 23.6 (21.2–25.7)
Etiology
   HBV 166 (63.3)
   HCV 24 (9.2)
   Alcoholic 40 (15.3)
   Others 32 (12.2)
Laboratory data
   Hemoglobin, g/dL  13.6 (11.8–14.8)
   Platelet count, 109/L 145 (94–186)
   Serum albumin, g/dL 4.2 (3.7–4.4)
   Prothrombin time, INR 1.0 (1.0–1.2)
   Aspartate aminotransferase, IU/L 35 (25–46)
   Alanine aminotransferase, IU/L 25 (15–37)
   Total bilirubin, mg/dL 0.8 (0.6–1.2)
Child-Pugh class A/B 244 (93.1)/18 (6.9)
Esophageal varix 83 (31.7)
   Small/medium/large 38/27/18
High-risk esophageal varix  49 (18.7)
Portal hypertensive gastropathy 24 (9.9)
ARFI velocity, m/sec 1.7 (1.3–2.5)
Spleen diameter, cm 10.1 (9.0–12.0)
ASPS 1.16 (0.66–2.84)
Data are presented as the median (interquartile range), number (%), or 
number.
HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international nor-
malized ratio; ARFI, acoustic radiation force impulse; ASPS, ARFI–
spleen diameter-to-platelet ratio score.
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normalized ratio (INR; 1.1 vs 1.0), a lower platelet count (89×109/
L vs 159×109/L), a higher ARFI velocity (2.5 m/sec vs 1.5 m/
sec), a larger spleen diameter (12.8 cm vs 9.5 cm), and a higher 
ASPS score (3.58 vs 0.85) (all p<0.05). The AUROC of the ASPS 
for predicting the presence of EVs at enrollment was 0.880 (95% 
confidence interval [CI], 0.838 to 0.923; p<0.001). 
When patients with and without HEVs were compared (Table 
2), the proportion of patients with large EVs and hypertensive 
gastropathy was significantly higher in the HEV group than in 
the non-HEV group (36.7% vs 0%, 20.4% vs 8.5%, respectively; 
all p<0.05). Patients with HEVs showed significantly lower he-
moglobin levels (median: 12.0 g/dL vs 13.8 g/dL), lower serum 
albumin level (3.9 g/dL vs 4.2 g/dL), higher INR (1.1 vs 1.0), 
lower platelet count (73×109/L vs 153×109/L), higher ARFI ve-
locity (2.5 m/sec vs 1.5 m/sec), larger spleen diameter (13.0 cm 
vs 9.9 cm), and a higher ASPS score (3.68 vs 1.00) (all p<0.05). 
The AUROC of the ASPS for predicting the presence of HEV at 
enrollment was 0.790 (95% CI, 0.720 to 0.860; p<0.001).
3. Incidence of EVB in the entire study population
The median follow-up period of the whole population was 38 
months (IQR, 31 to 51 months). During the study period, 22 pa-
tients experienced their first EVB episodes. The cumulative in-
cidence of EVB at 1 and 3 years was 0.76% and 4.96%, respec-
Table 2. Comparison between Patients with and without EV or HEV
Variable
Patients without EV
(n=179, 68.3%)
Patients with EV
(n=83, 31.7%)
p-value
Patients without HEV
(n=213, 81.3%)
Patients with HEV
(n=49, 18.7%)
p-value
Demographic data
   Age, yr 56 (46–63) 57 (49–65) 0.047  56 (47–63) 57 (49–65) 0.083
   Male sex 105 (58.7) 60 (72.3) 0.028 130 (61.0) 35 (71.4) 0.176
   Body mass index, kg/m2 23.7 (21.2–25.6) 23.6 (21.2–26.4) 0.580 23.9 (21.2–25.7) 23.4 (21.2–25.5) 0.932
Etiology
   Viral/non-viral 134 (74.9)/45 (25.1) 56 (67.5)/27 (32.5) 0.142 161 (75.6)/52 (24.4) 29 (59.2)/20 (41.8) 0.100
EVs
   Small-medium/large - 65 (78.3)/18 (21/7) - 34 (16.0)/0 31 (63.3)/18 (36.7) <0.001
Portal hypertensive gastropathy 6 (3.4) 61 (73.5) <0.001 18 (8.5) 10 (20.4) 0.014
Laboratory data
   Hemoglobin, g/dL  13.7 (12.0–14.8)  12.7 (10.5–15.0) 0.012  13.8 (12.0–15.0)  12.0 (10.5–14.1) 0.006
   Aspartate aminotransferase, IU/L 31 (23–42) 40 (30–50) 0.159 32 (24–42) 42 (32–51) 0.293
   Alanine aminotransferase, IU/L 26 (14–37) 22 (15–37) 0.206 25 (15–37) 22 (15–37) 0.099
   Serum albumin, g/dL 4.2 (3.9–4.4) 3.9 (3.5–4.3) <0.001 4.2 (3.8–4.4) 3.9 (3.2–4.2) <0.001
   Total bilirubin, mg/dL 0.8 (0.6–1.1) 1.1 (0.8–1.8) 0.252 0.8 (0.6–1.1) 1.2 (0.7–1.7) 0.221
   Prothrombin time, INR 1.0 (1.0–1.1) 1.1 (1.0–1.3) <0.001 1.0 (1.0–1.1) 1.1 (1.0–1.2) 0.003
   Platelet count, 109/L  159 (125–214) 89 (61–125) <0.001  153 (107–202) 73 (55–125) <0.001
ARFI, m/sec 1.5 (1.2–2.0) 2.5 (1.8–2.8) <0.001 1.5 (1.3–2.2) 2.5 (1.9–2.9) <0.001
Spleen diameter, cm 9.5 (8.5–10.8) 12.8 (10.1–14.5) <0.001  9.9 (8.7–11.0)  13.0 (10.5–14.5) <0.001
ASPS 0.85 (0.54–1.47) 3.58 (2.06–5.28) <0.001  1.00 (0.62–1.97)  3.68 (1.85–5.42) <0.001
Data are presented as the median (interquartile range) or number (%).
EV, esophageal varix; HEV, high-risk EV; INR, international normalized ratio; ARFI, acoustic radiation force impulse; ASPS, ARFI–spleen diame-
ter-to-platelet ratio score.
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Fig. 1. Cumulative EVB incidence according to the ASPS cutoff value 
of 2.60 in the entire population. The cumulative EVB incidence in pa-
tients with ASPS ≥2.60 was significantly higher than in patients with 
an ASPS ≥2.60 in the entire population (p<0.001 by the log-rank 
test). 
EV, esophageal varices; EVB, EV bleeding; ASPS, ARFI–spleen diam-
eter-to-platelet ratio score.
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tively. The AUROC of the ASPS for predicting the presence of 
EVB at enrollment was 0.824 (95% CI, 0.742 to 0.908; p<0.001). 
The ASPS cutoff value for predicting EVB was 2.60, a point at 
which the sum of the sensitivity (73.1%) and specificity (78.4) 
was maximized. The cumulative EVB incidence in patients with 
an ASPS ≥2.60 was significantly higher than that in those with 
an ASPS <2.60 (p<0.001) (Fig. 1).
When patients with and without EVB were compared (Table 
3), patients with EVB were significantly older (p=0.005). In ad-
dition, the proportion of patients with non-viral etiology, large 
EV, and hypertensive gastropathy was significantly higher in 
the EVB group (54.5% vs 24.6%, 27.2% vs 12.7%, 45.5% vs 
7.6%, respectively; all p<0.05). Patients with EVB had signifi-
cantly lower hemoglobin levels (median: 12.0 g/dL vs 13.7 g/
dL), lower serum albumin level (3.7 g/dL vs 4.2 g/dL), higher 
INR (1.2 vs 1.0), lower platelet count (81×109/L vs 149×109/L), 
higher ARFI velocity (2.8 m/sec vs 1.7 m/sec), larger spleen di-
ameter (12.5 cm vs 10.0 cm), and a higher ASPS score (4.79 vs 
1.07) (all p<0.05). 
4. Risk assessment of EVB in the subgroup with pre-exist-
ing EVs 
Among patients with EVs (n=83), 49 had HEVs, 22 (15 with 
HEV, seven with low-risk EV) of whom experienced EVB during 
the follow-up period. In this subgroup, the cumulative incidence 
rate of EVB at 1 and 3 years was 11.30% and 24.51%, respec-
tively. When patients with EVs were stratified into low-risk EV 
Table 3. Comparison between Patients with and without EVB
Variable
Patients without EVB
(n=240, 91.6%)
Patients with EVB
(n=22, 8.4%)
p-value
Demographic data
   Age, yr    55 (48–63)  64 (54–72) 0.005
   Male sex 146 (61.9) 16 (72.7) 0.324
   Body mass index, kg/m2 23.9 (21.2–25.8)  23.1 (21.9–25.2) 0.963
Etiology
   Viral/non-viral 179 (75.4)/58 (24.6) 10 (45.5)/12 (54.5) 0.002
EVs
   Small-medium/large 49 (20.8)/30 (12.7) 16 (72.8)/6 (27.2) <0.001
Portal hypertensive gastropathy 18 (7.6) 10 (45.5) <0.001
Laboratory data
   Hemoglobin, g/dL  13.7 (12.0–14.9) 12.0 (9.9–14.4) 0.031
   Aspartate aminotransferase, IU/L 34 (25–45) 41 (34–71) 0.107
   Alanine aminotransferase, IU/L 25 (15–37) 23 (15–43) 0.441
   Serum albumin, g/dL 4.2 (3.7–4.4) 3.7 (3.5–4.2) 0.009
   Total bilirubin, mg/dL 0.8 (0.6–1.2) 1.2 (0.8–2.1) 0.282
   Prothrombin time, INR 1.0 (1.0–1.1) 1.2 (1.0–1.3) <0.001
   Platelet count, 109/L 149 (99–195) 81 (56–108) <0.001
ARFI, m/sec 1.7 (1.3–2.2) 2.8 (2.3–3.4) <0.001
Spleen diameter, cm 10.0 (8.8–11.9) 12.5 (10.0–14.5) 0.001
ASPS 1.07 (0.63–2.49) 4.79 (2.54–7.16) <0.001
Data are presented as the median (interquartile range) or number (%). 
EV, esophageal varix; EVB, EV bleeding; ARFI, acoustic radiation force impulse; ASPS, ARFI–spleen diameter-to-platelet ratio score.
Fig. 2. Cumulative EVB incidence in patients with LEV and HEV. The 
cumulative incidence of EBV of patients with HEV was significantly 
higher than that of patients with LEV (p=0.037, log-rank test).
EV, esophageal varices; EVB, EV bleeding; LEV, low-risk; HEV, high-
risk EV.
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and HEV groups, the incidences at 1 and 3 years in patients 
with low-risk EVs were 8.83% and 17.87%, respectively, (n=34), 
while in patients with HEV, they were 13.12 and 30.52, respec-
tively (n=49) (p=0.037 on the log-rank test) (Fig. 2). 
5. Risk assessment of EVB in the subgroup with pre-exist-
ing HEVs
Based on the Korean management guidelines for liver cir-
rhosis, 49 patients with high-risk EV were treated with a nonse-
lective β-blocker (n=14, 28.6%) or endoscopic variceal ligation 
(n=35, 71.4%). However, during the follow-up period, 15 of 
these patients experienced their first EVB. When an ASPS of 
4.50, the point at which the sum of the sensitivity (66.7%) and 
specificity (70.6%) was maximized (AUROC, 0.691; 95% CI, 
0.516 to 0.866; PPV of 17.2%; NPV of 50.0%; negative likeli-
hood ratio, 0.5; positive likelihood ratio, 2.3) was selected, pa-
tients with an ASPS ≥4.50 showed significantly lower hemoglo-
bin levels (median: 11.5 g/dL vs 14.0 g/dL), lower platelet count 
(median: 58×109/L vs 107×109/L), higher proportion of HEV 
(78.6% vs 50.9%) and portal hypertensive gastropathy (46.4% 
vs 16.4%), higher ARFI velocity (median: 2.6 m/sec vs 2.3 m/
sec), and larger spleen diameter (median: 14.5 cm vs 11.4 cm) (all 
p<0.05) (Table 4). 
Among patients with HEV, those with a high ASPS showed a 
significantly higher cumulative EVB incidence than those with 
a low ASPS (p=0.045 by log-rank test); the incidence at 1 and 
3 years was 7.72% versus 20.17% and 20.56% versus 45.36%, 
respectively (Fig. 3). In addition, a higher ASPS independently 
predicted EVB among patients with HEV (hazard ratio, 1.330; 
p=0.017), together with age and the presence of portal hyper-
tensive gastropathy (Table 5).
DISCUSSION
Advances in noninvasive methods for assessing liver fi-
brosis have enabled the diagnosis of cirrhosis in the early 
compensated stage. Despite being asymptomatic, all cirrhosis 
patients are recommended to undergo screening endoscopy to 
Table 4. Comparison of Patients with EVs According to ASPS Value
Variable
Patients with ASPS <4.50
(n=55, 66.2%)
Patients with ASPS ≥4.50
(n=28, 33.8%)
p-value
Age, yr 59 (48–66)  56 (51–61) 0.739
Male sex 29 (70.9) 21 (75.0) 0.694
Body mass index, kg/m2 23.7 (20.5–26.5)  23.3 (22.3–25.9) 0.419
Hemoglobin, g/dL 14.0 (10.5–15.0)  11.5 (10.1–14.0) 0.047
Aspartate aminotransferase, IU/L 39 (29–49) 41 (31–55) 0.814
Alanine aminotransferase, IU/L 21 (15–37) 25 (19–45) 0.422
Serum albumin, g/dL 4.0 (3.5–4.3)  3.7 (3.5–4.2) 0.284
Total bilirubin, mg/dL 1.0 (0.6–1.6)  1.5 (1.0–2.5) 0.090
Prothrombin time, INR 1.1 (1.0–1.2) 1.2 (1.0–1.4) 0.159
Platelet count, 109/L 107 (84–141) 58 (45–72) <0.001
High-risk EV 28 (50.9) 22 (78.6) 0.034
Portal hypertensive gastropathy 9 (16.4) 13 (46.4) 0.006
ARFI velocity, m/sec 2.3 (1.7–2.8)  2.6 (2.3–3.1) 0.022
Spleen diameter, cm 11.4 (9.9–13.3)  14.5 (12.9–15.5) <0.001
Data are presented as the median (interquartile range) or number (%).
EVs, esophageal varices; ARFI, acoustic radiation force impulse; ASPS, ARFI–spleen diameter-to-platelet ratio score; INR, international normalized 
ratio.
Fig. 3. Among patients with HEV, the cumulative EVB incidence of 
patients with a high ASPS was significantly higher than that of pa-
tients with a low ASPS (p=0.045, log-rank test). 
EV, esophageal varices; HEV, high-risk EV; ASPS, acoustic radiation 
force impulse–spleen diameter-to-platelet ratio score.
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determine whether primary prophylactic treatment should be 
considered.1,9,10 Moreover, repeated endoscopic surveillance is 
also recommended to monitor the potential risk of HEVs.5,11 If 
there is a noninvasive way to determine the presence of HEVs 
that require prophylactic therapy, many low-risk patients could 
avoid unnecessary endoscopy screening. Thus, Park et al.17 re-
cently suggested a noninvasive ARFI-based prediction model 
for diagnosing HEVs in patients with compensated cirrhosis. In 
that study, the ARFI-based prediction model, named the ASPS, 
exhibited accurate diagnostic performance in predicting HEVs 
with an AUROC of 0.946. Additionally, the study also showed 
acceptable performance for the validation set with an AUROC of 
0.814. However, no study has investigated the predictive value 
of an ARFI-based prediction model to assess the risk of predict-
ing EVB in patients with cirrhosis. Here, we assessed the risk 
of EVB using ASPS cutoffs. Among patients with a high ASPS 
>4.50, those with HEV comprised a significantly higher percent-
age than those with an ASPS below the cutoff (59.2% vs 40.8%; 
p=0.045). In addition, a higher ASPS independently predicted 
EVB among patients with HEV (hazard ratio, 4.072; p=0.047).
LS by TE has represented a major advancement in the nonin-
vasive prediction of EVB. Most studies have shown that patients 
with an LS of 20 to 21 kPa are at high risk of developing EVB.23,24 
Kim et al.12 developed an LS-based prediction model, the LSPS. 
A high LSPS (≥6.5) was a significant predictor of EVB. Spleen 
stiffness (SS) assessed by TE was recently proposed as an indi-
cator closely related to portal hypertension.25,26 Buechter et al.24 
showed that patients with a high SS levels (>42.6 kPa) are at 
higher risk for EVB. Furthermore, that study suggested an algo-
rithm combining LS and SS to identify patients at low risk for 
bleeding; this algorithm showed an NPV up to 1.0. Few stud-
ies have assessed the risk of EVB, compared to studies focused 
on LS or SS, in patients with cirrhosis based on ARFI imaging, 
which is why we conducted this study. ARFI imaging can be 
obtained during ultrasonography examinations performed by 
the same sonographer and thus does not require additional 
equipment or personnel. ARFI-based risk evaluations may be 
helpful in a medical environment without TE or for patients 
who are limited to examinations by TE because of obesity or 
abundant ascites.27 
This study has several limitations. First, because of its retro-
spective design, it was susceptible to potential selection bias. It 
was also difficult to strictly control the interval between ARFI 
and endoscopy. Compared to our previous prospective study 
that limited the time between ARFI and endoscopy to within 
3 months,17 this study limited the interval to within 6 months. 
Another problem is that patients in our study population with 
an ASPS <4.50 still had many HEVs compared with patients 
with ASPS ≥4.50 (50.9% vs 78.6%). Although we selected a 
point that maximize the sum of the sensitivity and specificity, 
the small size of our study population might have limited tar-
geting a clinically significant cutoff. Thus, further large-scale 
studies might enable the establishment of an accurate cutoff. 
In addition, the study lacks a comparison with LS and SS, the 
latter of which is a highly suspected noninvasive parameter 
used to predict the effect of portal hypertension and EVB.15 Sec-
ond, we could not propose a management strategy for patients 
with low-risk EVs but a high ASPS due to the extremely small 
sample size. However, more careful follow-up strategy to detect 
the progression to HEV might be required for the patients with 
Table 5. Independent Predictors of EVB among Patients with HEV
Variable
Univariate analysis Multivariate analysis
p-value HR (95% CI) p-value HR (95% CI)
Age, yr 0.034 1.072 (1.005–1.143) 0.008 1.136 (1.034–1.248)
Male gender 0.625 1.389 (0.372–5.181) - -
Use of nonselective β-blocker (vs no use) 0.382 0.523 (0.122–2.239) - -
Large EV (vs small-medium EV) 0.753 1.222 (0.350–4.265) - -
Child-Pugh class A (vs B) 0.818 1.058 (0.652–1.717) - -
Hemoglobin, g/dL 0.965 0.994 (0.752–1.313) - -
Aspartate aminotransferase, IU/L 0.410 1.005 (0.993–1.019) - -
Alanine aminotransferase, IU/L 0.461 1.010 (0.983–1.038) - -
Serum albumin, g/dL 0.449 1.471 (0.541–3.997) - -
Total bilirubin, mg/dL 0.903 1.035 (0.597–1.792) - -
Platelet count, 109/L 0.169 0.990 (0.975–1.004) - -
NSBB (vs EVL) 0.378 0.565 (0.159–2.011) - -
Portal hypertensive gastropathy 0.032 5.000 (1.152–21.706) 0.017 11.067 (1.535–79.805)
ASPS 0.028 1.330 (1.032–1.715) 0.017 1.466 (1.070–2.008)
EV, esophageal varix; EVB, EV bleeding; HEV, high-risk EV; HR, hazard ratio; CI, confidence interval; NSBB, nonselective beta-blocker; EVL, en-
doscopic varix ligation; ASPS, acoustic radiation force impulse–spleen diameter-to-platelet ratio score.
Heo JY, et al: Acoustic Radiation Force Impulse Elastography-Based Esophageal Varix Bleeding Prediction Model  213
LEV but a high ASPS, although further studies are required to 
validate this hypothesis. Finally, because the hepatic venous 
pressure gradient was not obtained invasively (the gold stan-
dard for diagnosing portal hypertension), quantitative analysis 
of various parameters, including ARFI elastography, could not 
be performed. 
In conclusion, the ASPS, an ARFI-based noninvasive predic-
tion model, was helpful in assessing the risk of EVB in patients 
with cirrhosis. Prophylactic management should be considered 
for patients with HEV and an ASPS ≥4.50. 
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